Adeno-associated virus expressing a blood-brain barrier–penetrating enzyme improves GM1 gangliosidosis in a preclinical model
Saki Kondo Matsushima, … , Toya Ohashi, Hiroshi Kobayashi
Saki Kondo Matsushima, … , Toya Ohashi, Hiroshi Kobayashi
Published April 8, 2025
Citation Information: J Clin Invest. 2025;135(12):e180724. https://doi.org/10.1172/JCI180724.
View: Text | PDF
Research Article Genetics

Adeno-associated virus expressing a blood-brain barrier–penetrating enzyme improves GM1 gangliosidosis in a preclinical model

Abstract

GM1 gangliosidosis is a lysosomal storage disorder (LSD) caused by genetic defects in lysosomal β-galactosidase (β-gal). The primary substrate of β-gal is GM1 ganglioside (GM1), a sialylated glycosphingolipid abundant in the central nervous system (CNS). Deficiency in β-gal causes GM1 to accumulate in neural cells, leading to a rapid decline in psychomotor functions, seizures, and premature death. There is currently no therapy available. Although enzyme replacement therapy has been approved for other LSDs, its effects on the CNS are limited owing to the blood-brain barrier (BBB). Here, we assessed the therapeutic efficacy of a systemic infusion of an adeno-associated virus vector carrying a gene expressing a BBB-penetrable enzyme under the control of a liver-specific promoter in GM1 gangliosidosis model mice. The BBB-penetrable enzyme consisted of the variable region of the anti–transferrin receptor antibody fused with β-gal. The BBB-penetrable enzyme was only produced in the liver and secreted into the blood, which was efficiently distributed to various organs, including the brain. GM1 accumulation in the CNS was completely normalized, with improved neurological functions and animal survival. This therapeutic approach is expected to be applied for the treatment of several hereditary neurological diseases with CNS involvement.

Authors

Saki Kondo Matsushima, Yohta Shimada, Masafumi Kinoshita, Takashi Nagashima, Shinichiro Okamoto, Sayoko Iizuka, Haruna Takagi, Shunsuke Iizuka, Takashi Higuchi, Hiroyuki Hioki, Ayako M. Watabe, Hiroyuki Sonoda, Toya Ohashi, Hiroshi Kobayashi

×

Figure 4

T improves several motor performances.

Options: View larger image (or click on image) Download as PowerPoint
T improves several motor performances. Behavioral evaluation with rotaro...
Behavioral evaluation with rotarod test, open-field test, and gait analysis was conducted. (A) Rotarod testing: highest latency achieved on 4–40 rpm accelerating rotarod over 300 seconds over 3 trials (n = 8 for T-Low group, n = 10 for G-Low, T-High, and NT groups, n = 11 for G-High group, n = 19 for WT group). (B–D) Open-field test. Total distance traveled (B), rearing number (C), and moving speed (D) were analyzed (n = 8 for T-Low group, n = 9 for G-Low and T-High groups, n = 11 for G-High group, n = 10 for NT group, n = 19 for WT group). (E) Gait analysis (n = 12 for T-Low group, n = 15 for T-High and NT groups, n = 18 for G groups, n = 21 for WT group). Footprints were evaluated for stride length/body length ratio. G-Low, 1 × 1012 vg/kg of AAV-β-gal treatment; G-High, 5 × 1012 vg/kg of AAV-β-gal treatment; T-Low, 1 × 1012 vg/kg of AAV-Tβ-gal treatment; T-High, 5 × 1012 vg/kg of AAV-Tβ-gal treatment; NT, nontreated GM1 mice; WT, wild-type mice. Results are shown as means ± SEM. Significance was evaluated by a 1-way ANOVA followed by Tukey’s or Dunnett’s multiple-comparison test. *P < 0.05, **P < 0.005, ****P < 0.0001.